首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Targeting the immunity protein kinases for immuno-oncology
【24h】

Targeting the immunity protein kinases for immuno-oncology

机译:针对免疫肿瘤学的免疫蛋白激酶

获取原文
获取原文并翻译 | 示例
           

摘要

With the rise of immuno-oncology, small-molecule modulators targeting immune system and inflammatory processes are becoming a research hotspot. This work mainly focuses on key kinases acting as central nodes in immune signaling pathways. Although over thirty small-molecule kinase inhibitors have been approved by FDA for the treatment of various cancers, only a few are associated with immuno-oncology. With the going deep of the research work, more and more immunity protein kinase inhibitors are approved for clinical trials to treat solid tumors and hematologic malignancies by FDA, which remain good prospects. Meanwhile, in-depth understanding of biological function of immunity protein kinases in immune system is pushing the field forward. This article focuses on the development of safe and effective small-molecule immunity protein kinase inhibitors and further work needs to keep the promises of these inhibitors for patients' welfare. (C) 2018 Published by Elsevier Masson SAS.
机译:随着免疫肿瘤学的兴起,靶向免疫系统和炎症过程的小分子调节剂正在成为一个研究热点。 这项工作主要集中在关键激进酶上,作为免疫信号通路中的中央节点。 虽然FDA已经通过FDA批准了30多个小分子激酶抑制剂,但仅少量与免疫肿瘤有关。 随着研究工作的深刻,越来越多的免疫蛋白激酶抑制剂被批准用于临床试验,以治疗FDA治疗固体肿瘤和血液学恶性肿瘤,这仍然是良好的前景。 同时,深入了解免疫系统中免疫蛋白激酶的生物功能正在推动该场。 本文侧重于开发安全有效的小分子免疫蛋白激酶抑制剂,进一步的工作需要保持这些抑制剂对患者福利的承诺。 (c)2018由Elsevier Masson SA发布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号